Sign in

You're signed outSign in or to get full access.

Peter Liu

Peter Liu

Chief Executive Officer at DNA XDNA X
CEO
Executive
Board

About Peter Liu

Peter Hao Liu is Chief Executive Officer of Sonim Technologies and a director since July 2022; he has an MBA from Lawrence Technological University and a Bachelor’s in Engineering from Tianjin University, and was age 56 as of June 20, 2024 . He has led operations at Sonim since 2010 prior to becoming CEO in April 2022 and is not an independent director; the Board maintains an independent chair and holds regular executive sessions to mitigate dual‑role risks . Recent pay-versus-performance disclosures show Compensation Actually Paid to the PEO and TSR volatility: $2.14M CAP in 2023 vs $(0.13)M in 2024 with TSR index dropping from $79.72 (2023) to $34.23 (2024), alongside net losses of $(33.65)M in 2024 . Revenues fell from $93.6M in FY2023 to $58.3M in FY2024; quarterly revenue mix in 2025 shows variability with Q1 $16.7M, Q2 $11.2M, Q3 $16.2M .

Past Roles

OrganizationRoleYearsStrategic Impact
Sonim TechnologiesEVP, Global Operations2010–2022Led global operations through supply chain/quality transitions pre-CEO
LOM/PerlosGlobal Quality Director2007–2010Quality leadership for international VI supplier to mobile OEMs
Motorola SolutionsHead of Quality, Strategic Growth Engine2005–2007Drove quality programs supporting growth initiatives

External Roles

  • No current public company directorships or external board roles disclosed in proxy biography .

Fixed Compensation

Metric202220232024
Base Salary ($)$396,250 $450,000 $450,000
Target Bonus %Not disclosed Not disclosed Not disclosed
Actual Bonus Paid ($)$0 $180,000 $175,630
All Other Compensation ($)$89,319 (incl. housing/car allowances) $47,226 (primarily housing/car allowances) $47,288 (primarily housing/car allowances)
Director FeesNone (CEO-director receives no director compensation) None None

Performance Compensation

Equity and Incentive Awards

Award TypeGrant DateShares/UnitsStrike/Grant ValueVesting ScheduleExpiration
Stock Options11/18/2022150,903 exercisable; 150,540 unexercisable$4.18810 equal quarterly installments from Jan 14, 2024 to Apr 14, 202610/26/2032
Stock Option12/02/2019500$248.00Not disclosed12/01/2029
Stock Option06/30/201567$150.00Not disclosed06/30/2025
Options under A&R Employment AgreementVarious (aggregate)401,443Not disclosed1/4 vests on first anniversary of CEO appointment; remaining 3/4 vests in equal quarterly installments thereafter (4-year schedule)Max term 10 years per grant
  • Performance plan mechanics: Company’s 2019 Plan permits performance awards (stock/cash) tied to metrics such as revenue, EBITDA, TSR, ROE/ROA, margin, cash flow, and others; there is no automatic single-trigger vesting on change-in-control, and awards are subject to clawback per Nasdaq Rule 10D-1 .

Annual Incentive Plan Details

MetricWeightingTargetActualPayoutVesting
Annual Cash Bonus (CEO)Not disclosedNot disclosed$180,000 (2023) ; $175,630 (2024) PaidCash; no vesting

Equity Ownership & Alignment

ItemValue
Total beneficial ownership514,528 shares (includes options to purchase 245,140 shares exercisable within 60 days of 9/15/2025)
Ownership % of outstanding2.85% (as of record date 9/15/2025)
Options exercisable (≤60 days)245,140 shares
Options unexercisable (not within 60 days)150,540 shares (from 11/18/2022 grant)
RSUs outstandingNone outstanding as of 9/15/2025 per plan disclosures
Hedging/PledgingProhibited by Insider Trading Policy (short sales, options, hedging, margin, pledges)
Ownership guidelinesNot disclosed in proxy for executives

Employment Terms

ProvisionTerms
Employment agreementAmended and restated 12/8/2023; at-will; base salary $450,000; options granted under EIP; confidentiality, non-disparagement, cooperation provisions
Severance (Change-in-Control)If terminated without cause or resigns for “good reason” within 12 months of a change-in-control: lump-sum equal to 150% of base salary plus guaranteed pro-rated bonus; paid within 30 days
Equity treatment on CICPlan does not provide automatic single-trigger vesting on change-in-control; acceleration may be specified in award agreements; no liberal CIC definition
Non-compete / Non-solicitNot disclosed in CEO agreement summary
Clawback policyCompany adopted a clawback policy for incentive-based compensation under Nasdaq and SEC Rule 10D‑1
Say-on-PayAs an Emerging Growth Company, Sonim is not required to conduct say‑on‑pay votes

Board Governance

  • Role: Director since 2022; not independent .
  • Committee memberships: None listed for CEO-director; Audit (Cassano Chair), Compensation (Mulica Chair), Nominating (Steenstra Chair) are composed of independent directors .
  • Board leadership: Independent Chair (Mike Mulica); Board meets in executive sessions without management .
  • Attendance: Each director attended ≥75% of Board and committee meetings in FY2023 .
  • Director compensation: CEO-director does not receive director compensation .

Performance & Track Record

Annual Fundamentals

MetricFY 2022FY 2023FY 2024
Revenues ($USD)$69.8M $93.6M $58.3M
EBITDA ($USD)$(11.1)M*$2.5M*$(29.9)M*

Values retrieved from S&P Global.*

Quarterly Fundamentals (latest 4)

MetricQ4 2024Q1 2025Q2 2025Q3 2025
Revenues ($USD)$14.98M $16.72M $11.19M $16.21M
EBITDA ($USD)$(21.01)M*$1.70M*$(5.94)M*$(3.03)M*

Values retrieved from S&P Global.*

Pay versus Performance and TSR

Metric202220232024
PEO Compensation Actually Paid ($)$1,975,045 $2,136,138 $(134,334)
TSR Index (Initial $100)$46.08 $79.72 $34.23
Net Income ($M)$(14.09) $(0.09) $(33.65)

Related Party and Capital Structure Developments

  • Initial officer selection was pursuant to a contractual arrangement tied to an equity investment by a stockholder (Jeffrey Wang), per proxy disclosure .
  • 2025 Special Meeting proposals include: reverse stock split authority (1-for-2 to 1-for-30), authorized share increase to 1,000,000,000, and EIP share increase by 1,000,000; cited rationale includes Nasdaq minimum bid price compliance and retention flexibility .
  • Rights plan adopted April 21, 2025 (limited duration poison pill) with mechanics around Preferred Shares and purchase price adjustments; expires April 21, 2026 .

Compensation Committee Analysis

  • Committee composition (independent directors) and use of independent consultant Compensia to advise on executive/director pay; no conflicts identified . The committee sets CEO goals, evaluates performance, sets incentive/equity compensation, and oversees pay-related risks .

Investment Implications

  • Alignment: Liu holds 2.85% beneficial ownership with significant vested options (245k exercisable within 60 days), suggesting moderate equity alignment; anti‑hedging/pledging policy reduces misalignment risk .
  • Incentive structure: Bonuses appear discretionary with limited disclosure of performance metrics, while equity compensation is option‑heavy with time‑based vesting; plan includes robust clawback and no single‑trigger CIC vesting .
  • Liquidity and selling pressure: 2022 option grants vesting through Apr 2026 and the absence of RSUs as of Sept 2025 may shift near‑term selling pressure around option exercises rather than RSU releases; the proposed 2025 EIP share increase indicates potential for future equity grants .
  • Execution risk and performance: Revenues contracted in FY2024 with negative EBITDA; TSR deteriorated materially in 2024; continued listing risk evidenced by minimum bid price issues and repeated reverse-split authority proposals .
  • Governance: Dual role as CEO-director is mitigated by independent Chair, independent committees, and regular executive sessions; CEO does not sit on committees and receives no director fees .